The company announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent covering method of use for COM902, the Company's potential best-in-class reduced Fc, clinical stage antibody targeting TIGIT, and additional TIGIT backup antibodies in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer.
Compugen Expands Its Intellectual Property Portfolio With New U.S. Patent Covering Triple Combination Use Of COM902 (Reduced FC Anti-TIGIT) With Anti-PD-1 And Anti-PVRIG Antibodies
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated